Dl-Tranylcypromine
Dl-Tranylcypromine Brand names, Dl-Tranylcypromine Analogs
Dl-Tranylcypromine Brand Names Mixture
- No information avaliable
Dl-Tranylcypromine Chemical_Formula
C9H11N
Dl-Tranylcypromine RX_link
http://www.rxlist.com/cgi/generic2/tranylcypromine.htm
Dl-Tranylcypromine fda sheet
Dl-Tranylcypromine msds (material safety sheet)
Dl-Tranylcypromine Synthesis Reference
No information avaliable
Dl-Tranylcypromine Molecular Weight
133.19 g/mol
Dl-Tranylcypromine Melting Point
79-80 oC at 1.50E+00 mm Hg
Dl-Tranylcypromine H2O Solubility
4.86E+004 mg/L
Dl-Tranylcypromine State
Solid
Dl-Tranylcypromine LogP
1.434
Dl-Tranylcypromine Dosage Forms
Tablets (10 mg, for oral administration)
Dl-Tranylcypromine Indication
For the treatment of major depressive episode without melancholia.
Dl-Tranylcypromine Pharmacology
Tranylcypromine belongs to a class of antidepressants called monoamine oxidase inhibitors (MAOIs). Tranylcypromine is a non-hydrazine monoamine oxidase inhibitor with a rapid onset of activity. It increases the concentration of epinephrine, norepinephrine, and serotonin in storage sites throughout the nervous system and, in theory, this increased concentration of monoamines in the brain stem is the basis for its antidepressant activity.
Dl-Tranylcypromine Absorption
No information avaliable
Dl-Tranylcypromine side effects and Toxicity
In overdosage, some patients exhibit insomnia, restlessness and anxiety, progressing in severe cases to agitation, mental confusion and incoherence. Hypotension, dizziness, weakness and drowsiness may occur, progressing in severe cases to extreme dizziness and shock. A few patients have displayed hypertension with severe headache and other symptoms. Rare instances have been reported in which hypertension was accompanied by twitching or myoclonic fibrillation of skeletal muscles with hyperpyrexia, sometimes progressing to generalized rigidity and coma.
Dl-Tranylcypromine Patient Information
Dl-Tranylcypromine Organisms Affected
Humans and other mammals
